Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use CALQUENCE safely and effectively. See full prescribing information for CALQUENCE.CALQUENCE® (acalabrutinib) tablets, for oral useInitial U.S. Approval: 2017
Medication labelWhy this: Advisory · dailymed-prescription
CALQUENCE in combination with bendamustine and rituximab is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). CALQUENCE is indicated for the treatment of adult patients with MCL who have received at least one prior therapy. CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- generic_name
- acalabrutinib
- product_names
- acalabrutinib
- ndc
- 0310-3512, 0310-3512-60, 0310-3512-95, 0310-4513, 0310-4513-60
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en